Born in silico, a new approach to drug design (I'MTech)
03 March 2026
Discovering a new drug has long been a lengthy, costly, and uncertain process, marked by high failure rates. At Télécom Paris, Pavlo Mozharovskyi research explores how robust statistics and artificial intelligence are profoundly transforming molecule screening, particularly for applications related to aging.
- Every new drug is th result of a monumental task of sorting through millions of possible molecules.
- Before discovering an effective molecule, candidates worthy of testing must be identified.
- Research at Télécom Paris combines robust statistics and AI to increase the efficiency of this selection process.
Statistical tools put to the test
[…] A researcher at Télécom Paris, Pavlo Mozharovskyi specializes in developing advanced machine learning and computational statistics methods. In particular, he studies data depth, which makes it possible to evaluate the centrality of an observation and, by extension, identify what deviates from it. Initially developed for the classification of complex data and the detection of anomalies, these methods can be used to screen molecules by comparing them with each other in order to select relevant candidates.[…]